Study on BMS-986482 Alone or in Combination for Advanced Solid Tumors

Inclusion Criteria

• Must have a confirmed diagnosis of advanced solid cancer that cannot be removed by surgery or has spread, and must have tried or be unable to try other treatments that could help.
• Must be 18 years or older.
• For Part 1A, participants may have certain types of cancer such as lung, head and neck, colorectal, stomach, bladder, pancreatic, melanoma, or breast cancer.
• For Parts 1B1 and 2B1, participants must have non-small cell lung cancer (NSCLC) and should know the status of certain genetic mutations if possible. They must have had platinum-based chemotherapy and anti-PD-(L)1 therapy if eligible.
• For Parts 1B2, 2B2, and 1C, participants must have certain types of melanoma, but not uveal/ocular melanoma, and must have had at least one prior treatment.
• For Part 1B3, participants must have advanced or metastatic colorectal cancer.
• For Part 2A, participants may have advanced solid tumors like NSCLC, hormone-resistant breast cancer, or pancreatic cancer.
• For Part 2B3, participants must have advanced or metastatic colorectal cancer.
• For Part 1C, a fresh tumor sample must be obtained if possible.

Exclusion Criteria

• History of severe immune-related side effects from previous T-cell or checkpoint inhibitor treatments, unless they are unlikely to happen again with standard treatments.
• Any serious medical condition that could interfere with the study or follow-up, as determined by the study doctor.
• Other specific criteria as defined by the study protocol.